In conclusion, we have shown that low-level SAMHD1 expression in AML blasts at diagnosis identifies a sizeable patient subset with favorable EFS and OS upon treatment with HDAC-containing consolidation regimens. This evidence concerns the gene SAMHD1 and acute myeloid leukemia.